@alzeca.com
Alzeca Biosciences develops novel advanced imaging agents for the early diagnosis of neurodegenerative diseases, including Alzheimer’s Disease.
📢
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
About
Description
Alzeca Biosciences, Inc. With an estimated 5. 5 million Americans and over 27 million patients worldwide affected by Alzheimer's, the need for effective diagnostic and treatment methods is crucial.
Alzeca recognizes the importance of early detection as disease pathology begins to accumulate 10 to 15 years before cognitive symptoms appear. By offering novel agents based on MRI and CT scanning technologies, Alzeca provides a cost-effective and widely available alternative to current PET scan methods. This means more individuals can have access to screening and diagnosis for these disorders, allowing for timely and accurate identification.
Supported by private investors and grants from renowned organizations like the Cure Alzheimer's Fund and the Alzheimer’s Association, Alzeca benefits from the expertise of its founders who possess over 25 years of experience in drug development. Moreover, the brand's leadership consists of world-renowned experts in diagnostic imaging innovation and clinical neuroscience, complemented by an experienced management team. Alzeca Biosciences is committed to revolutionizing the field of neurodegenerative disease diagnosis, ultimately improving patients' prognostic outcomes and enabling preemptive treatment for a more manageable future
Company Type
Privately Held
Company Size
2-10
Year Founded
2012
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere 👋
All services online